Alnylam Pharmaceuticals (ALNY) – Research Analysts’ Weekly Ratings Updates

Alnylam Pharmaceuticals (NASDAQ: ALNY) has recently received a number of price target changes and ratings updates:

• 1/13/2025 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
• 1/13/2025 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
• 1/9/2025 – Alnylam Pharmaceuticals was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 1/7/2025 – Alnylam Pharmaceuticals had its price target lowered by analysts at Sanford C. Bernstein from $314.00 to $310.00. They now have an “outperform” rating on the stock.
• 12/27/2024 – Alnylam Pharmaceuticals was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 12/18/2024 – Alnylam Pharmaceuticals was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 11/28/2024 – Alnylam Pharmaceuticals was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/19/2024 – Alnylam Pharmaceuticals had its “outperform” rating reaffirmed by analysts at William Blair.
• 11/18/2024 – Alnylam Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $296.00 price target on the stock.
• 11/18/2024 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $240.51 on Wednesday. The stock’s fifty day simple moving average is $248.15 and its 200 day simple moving average is $259.81. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The firm has a market cap of $31.02 billion, a price-to-earnings ratio of -91.80 and a beta of 0.34. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. The business’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.15 EPS. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,469 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the sale, the executive vice president now owns 13,191 shares in the company, valued at approximately $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 5,219 shares of the company’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the transaction, the chief executive officer now owns 78,880 shares in the company, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,122 shares of company stock valued at $2,540,455. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALNY. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $26,000. Dai ichi Life Insurance Company Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $262,000. Dimensional Fund Advisors LP increased its stake in shares of Alnylam Pharmaceuticals by 4.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 266,206 shares of the biopharmaceutical company’s stock valued at $64,702,000 after buying an additional 11,027 shares during the period. E Fund Management Co. Ltd. lifted its stake in shares of Alnylam Pharmaceuticals by 75.1% during the second quarter. E Fund Management Co. Ltd. now owns 4,926 shares of the biopharmaceutical company’s stock valued at $1,197,000 after acquiring an additional 2,112 shares during the period. Finally, Meiji Yasuda Asset Management Co Ltd. boosted its holdings in Alnylam Pharmaceuticals by 15.3% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,030 shares of the biopharmaceutical company’s stock valued at $493,000 after acquiring an additional 270 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.